We must not forget transgender patients’ physiology if we are to prescribe safely Pharmacists should always be respectful of patients’ identity wishes, but biological differences between the sexes mean that conflating sex and gender could have serious implications for prescribing.…
Scottish Pharmacy Board meeting: 22 January 2020 At the latest Royal Pharmaceutical Society Scottish Pharmacy Board meeting, discussions revolved around pharmacotherapy, science and research, and public affairs in Scotland.…
English Pharmacy Board meeting: 30 January 2020 At the latest Royal Pharmaceutical Society English Pharmacy Board meeting, discussions revolved around plans for science and research, and a digital edition of Medicines, Ethics and Practice.…
Welsh Pharmacy Board meeting: 5 February 2020 At the latest Royal Pharmaceutical Society Welsh Pharmacy Board meeting, discussions revolved around Brexit, medicines shortages and public affairs in Wales.…
Case-based learning: management of polycystic ovary syndrome As the most common incurable hormonal condition affecting women of reproductive age, polycystic ovary syndrome can lead to infertility, anxiety and cardiovascular disease if it is not managed appropriately.…
How employers can help support staff with disabilities Employers have a duty of care to support the health, safety and wellbeing of all employees, including those with disabilities.…
Considerations for the inpatient management of Parkinson’s disease Recognising and managing certain complications of Parkinson’s disease can help improve care and reduce the risk of admission for people living with the condition.…
Going against type: the new class of cancer therapies targeting mutations rather than tissues ‘Tumour agnostic’ drugs offer a more effective and tolerable therapy for a wide range of people with cancer, so why has the NHS rejected its first one?…
Funding to be made available for home deliveries, says NHS England and NHS Improvement The cost of delivering medicines to vulnerable patients who are self-isolating or have COVID-19 will be reimbursed, Simon Stevens, the chief executive of NHS England has said.…
Medicines regulator and NICE to review evidence of impact of NSAIDs on COVID-19 The Committee of Human Medicines — an advisory body of the Medicines and Healthcare products Regulatory Agency — and the National Institute for Health and Care Excellence are to review the evidence on the impact of non-steroidal anti-inflammatory drugs on the severity of COVID-19 infecti…
